Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
US6897295B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 16, 1996 |
| Grant date | May 24, 2005 |
| Priority date | — |
| Expiry date | Jul 16, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognizes the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polypeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant. This novel polypeptide has a cytoplasmic domain, a transmembrane domain and extracellular domain and takes part in apoptosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.